Humacyte stock has dropped 46% since July, mainly due to FDA review delays. Check out why I downgraded HUMA stock from "buy" ...

The following is a summary of “Effective and durable repigmentation for stable vitiligo: A randomized within-subject ...

I explained last Monday that there are, in general, two types of stem cell therapies. I started with the autologous stem cell ...

The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular ...

The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

Humacyte, Inc. announced that the FDA has granted full approval for the company’s Symvess—acellular tissue enginee ...

A study presented at the American Society of Hematology annual meeting explored how relationship dynamics, including satisfaction and strain, influence physical and emotional outcomes during ...

Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair ...

RNA Signature in CSF Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis,” published ...

As of Friday’s premarket trading session, Humacyte’s stock surged +33.52% to $4.62, reflecting investor optimism following this groundbreaking news. While the company’s stock has had a solid +21.83% ...

Humacyte (HUMA) announced that the FDA has granted a full approval for Symvess for use in adults as a vascular conduit for extremity arterial ...